Adipotide

Fat LossExperimental fat-vasculature targeting peptideExperimental

Also known as: FTPP, Prohibitin-targeting peptide

Adipotide (also called FTPP or Prohibitin-targeting peptide) is an experimental fat-vasculature targeting peptide in the Targeted peptidomimetic class. Adipotide is a peptidomimetic built from two functional parts joined together. The first is the homing sequence CKGGRAKDC, selected by phage display for binding prohibitin, a protein reported to be selectively displayed on the surface of endothelial cells in white adipose tissue vasculature.

Calculate Dose

For research use only.

Key Facts

CAS: 859216-15-2
Molecular Weight (MW): 2557.2 g/mol
Half-life: —
FDA status: Not Approved
Evidence level: Insufficient Evidence
Human dose established: No
Administration Route: Not established in humans
Frequency: Not established in humans
Last updated: Nov 7, 2026
Reviewed: Nov 7, 2026
Targets: Prohibitin (adipose vasculature)

Vendor price snapshot

Each vendor's price is the median price per mg of its own listings; with fewer than 3 vendors there is no typical range. From public vendor listings collected between Oct 2026 and Nov 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.

Vendors listing this peptide: 2
Listed offers: 3
Price per mg: $6.00–$7.75/mg

Open calculator · Compare vendors

Research summary

Experimental chimeric peptide designed to induce apoptosis in white-adipose vasculature via prohibitin targeting. Not FDA-approved; development did not yield a drug.

Research evidence

Regulatory review (FDA label)None in reviewed sources
Controlled human trialsNone in reviewed sources
Early or uncontrolled human studies1 reviewed source
Lab & animal studies1 reviewed source

How it works

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

Peptide Library's Adipotide profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.

Adipotide dosage: no established human dose

Adipotide has no established human dosage. Its main evidence is a 2011 study in obese monkeys. A first-in-human phase 1 trial in men with metastatic prostate cancer and obesity, registered as Prohibitin-TP01, started at 0.03 mg/kg under the skin daily for 28 days; it enrolled 4 patients, was terminated at the investigator's request, and posted no results.

Insufficient Evidence

No established human dosage.

Human clinical evidence: None identified.

Preclinical research: Adipotide is a peptidomimetic that targets blood vessels in white fat and triggers their cell death. In obese monkeys it caused rapid weight loss and improved insulin resistance, along with predictable, reversible changes in kidney tubule function. The one human trial gave a starting dose to four patients and reported nothing, so no human dose, route or interval is established.

Animal dosing is not converted into a human dose anywhere on this page. Where research figures appear below, they are reported as studied, not recommended.

Dosage evidence summary for Adipotide
Human dosing established	No
Route	Not established in humans
Evidence level	Insufficient Evidence
Last reviewed	2026-11-07

Human research reported

Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.

Research-reported dosing for Adipotide, one row per studied regimen
Study / context	Population	Dose	Route	Frequency	Duration	Outcome studied	Source
NCT01262664 — first-in-human phase 1, Prohibitin-TP01 (adipotide), terminatedClinical trial · Phase 1 dose-finding trial, terminated per the investigator's request	Men with metastatic prostate cancer and obesity (n=4 enrolled)	Starting dose 0.03 mg/kg; no results posted	Subcutaneous	Once daily	28 days (one cycle)	Safety and tolerability (no results posted)	NCT01262664 — A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity

Preclinical and analog research

Not human dosing evidence. Listed for completeness and never extrapolated to a human dose.

Research-reported dosing for Adipotide, one row per studied regimen
Study / context	Population	Dose	Route	Frequency	Duration	Outcome studied	Source
Obese Old World monkeys (2011)Preclinical · Primate study	Obese monkeys from three species	Experimentally determined doses (non-human)	Not stated in the indexed abstract	—	—	Weight loss and improved insulin resistance, with reversible changes in kidney tubule function	A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Sci Transl Med. 2011.

Where sources disagree

A phase 1 starting dose is the first step of a safety escalation, not a dose shown to be safe or effective. This trial stopped after four patients and posted no results.
Kidney tubule effects were seen in the primate study. No human safety data has been published.

Reconstitution

Common research vial sizes: 2 mg, 5 mg, 10 mg.

Reconstitution arithmetic for Adipotide
Vial	Bacteriostatic water	Concentration	Per 0.01 mL
5 mg	2 mL	2.5 mg/mL	25 mcg per 0.01 mL
10 mg	2 mL	5 mg/mL	50 mcg per 0.01 mL

These figures are arithmetic only — they convert a vial and a volume into a concentration. They are not a recommendation to take any dose.

Calculate reconstitution & dose →

Handling & administration

Injection Sites: AbdomenThigh
Timing Notes: Educational catalog only — not medical advice

Sequence & molecular data

Sequence and molecular data for Adipotide
Molecular formula	C111H206N36O28S2
Molecular weight	2557.2 g/mol
CAS number	859216-15-2
Appearance	White lyophilized powder
Formulation	Lyophilized Powder
PubChem CID	163360068

Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.

Science

Mechanism of Action

Adipotide is a peptidomimetic built from two functional parts joined together. The first is the homing sequence CKGGRAKDC, selected by phage display for binding prohibitin, a protein reported to be selectively displayed on the surface of endothelial cells in white adipose tissue vasculature. The second is a KLAKLAK dimer, a pro-apoptotic domain that is inactive outside cells but disrupts mitochondrial membranes once internalised. The design intent is targeted ablation of the blood supply to fat tissue rather than any action on adipocyte metabolism, causing adipose tissue to regress through loss of perfusion. In primate studies this produced weight reduction, but renal toxicity was observed, and development did not proceed.

Origin

Synthetic targeted peptidomimetic.

Targets

Prohibitin (adipose vasculature)

Studies

Research statistics

3 PubMed publications · 0.0% human clinical research · 0 registered trials

Counts of published research through 2026-11-01, not evidence that it works. Publications by year, study types and trials · How publications are counted

Regulatory & research status

Adipotide is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

Regulatory and research status for Adipotide
FDA status	Not Approved
Availability	Research-Only
WADA (sport)	Banned in Sport
Library classification	Research-Only

How FDA approval, compounding and research-only status differ

Benefits

Historical adipose-vasculature research

Adipotide side effects

Adipotide has no controlled human safety data. The effects below are reported, not established, and absence from the list is not evidence of safety.

Side Effects

Renal toxicity signal in animals
No human dose

Storage & stability

Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.

Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.

Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.

Read the full guide: how to store peptides before and after reconstitution →

Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.

Adipotide: frequently asked questions

What is Adipotide?

Experimental chimeric peptide designed to induce apoptosis in white-adipose vasculature via prohibitin targeting. Not FDA-approved; development did not yield a drug.

How does Adipotide work?

Is Adipotide FDA approved?

No. Adipotide is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

Is Adipotide banned in sport?

Adipotide is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.

What peptides are similar to Adipotide?

Compounds most often compared with Adipotide include 5-Amino-1MQ, AICAR, Angiotensin (1-7) Analog and AOD-9604. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

References

Related research, comparisons & guides

Related peptides

Angiotensin (1-7) Analog

Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 2

This Adipotide profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error

Track Adipotide research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →